

Research Article

Which antibiotics are active against *Lactobacillus iners* playing the prominent role in the female urobiome?

Herbert Hof^{1*}, Hofmann S¹

1. MVZ Labor Limbach und Kollegen, Heidelberg Im Breitspiel 1669126 Heidelberg, Germany.

How to cite this article: Hof H, Hofmann S. (2026). Which antibiotics are active against *Lactobacillus iners* playing the prominent role in the female urobiome? *Journal of Infectious Diseases and Therapeutic Research. RPC Publishers.* 2(1), 1-3.

Copyright license: © 2026 Herbert Hof, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Address for correspondence: Herbert Hof, MVZ Labor Limbach und Kollegen, Heidelberg Im Breitspiel 1669126 Heidelberg, Germany.

Email: herbert.hof@labor-limbach.de

Submitted: March 23, 2026

Approved: April 13, 2026

Published: April 27, 2026

Abstract

Urine is not sterile! *Lactobacillus iners* are the dominant agent in the human urobiome at least in women. These innocent bacteria attached firmly to the epithelium of the urinary bladder by strong interaction with the fibronectin on the surface of these cells. These colonizers inhibit uropathogenic bacteria to bind thus preventing the first step of an infection. Antibiotic therapy can interfere with the resident, protective flora. While ampicillin, pivmecillinam, cefotaxime, levofloxacin, nitroxoline and nitrofurantoin are active against *L. iners*. cotrimoxazole and fosfomycin are inactive.

Keywords: Urobiome; *Lactobacillus iners*; susceptible ampicillin; pivmecillinam; cefotaxime; levofloxacin; nitroxoline; and nitrofurantoin; resistant cotrimoxazole and fosfomycin.

Introduction

Urine is not sterile [1]! The female urinary bladder is generally colonized primarily by *Lactobacillus iners* [1], [3]. These bacteria adhere firmly to the fibronectin on the surface of epithelial cells and hence these gatekeepers inhibit uropathogenic bacteria to bind. Thus, the first step of infection is prevented by *L. iners*.

In principle, antibiotic therapy can interfere with the resident flora of the urinary bladder [4]. The question is, which antibiotics used usually to treat urinary tract infection or to prevent recurrent infections are active against *L. iners* and which ones are not harmful.

Materials and Methods

Lactobacillus iners strain 1533 was bought from the German Leibniz collection of microorganisms and cell cultures DSMZ/Braunschweig. This strain was originally isolated from urine. The antibiotic susceptibility was determined by a disk diffusion test using Brucella-Agar [Becton Dickinson, Heidelberg, Germany]. Incubation occurred at 36°C for 24 hours at a concentration of 5% CO₂.

Authoritative breakpoints from EUCAST for *Lactobacillus iners* do not exist; the assessment of the laboratory results was adapted as far as available according to the interpretation of Guerin [5] or if applicable to EFSA [6]. For nitroxoline a breakpoint of 16 mm was taken as recommended by NAK [7].

Results

The antimicrobial activities of a selection of antibiotics, usually used for the therapy and/or the prevention of urinary tract infections [8], against *L. iners* was determined in a disk diffusion test (tab.1).

Table 1: In vitro activity of several antibiotics on *Lactobacillus iners*

antibiotic	inhibition zone	activity
ampicillin	29 mm	active
pivmecillinam	21 mm	active
cefotaxime	38 mm	active
nitrofurantoin	42 mm	active
nitroxoline	25 mm	active
levofloxacin	30 mm	active
cotrimoxazole	7 mm	inactive
fosfomycin	<7 mm	inactive

Some of the tested antibiotics could inhibit the growth of *L. iners*, whereas some others don't (Table 1).

There may be, however, quantitative differences between some antibiotics, for example between nitroxoline and nitrofurantoin (fig. 1) as shown in the disk diffusion assay.



Figure 1: Comparative in vitro activity of nitroxoline (NIB 30) and nitrofurantoin F100) against *Lactobacillus iners* strain DMSZ 1533 on Brucella agar.

Discussion

More than 130 lactobacilli strains have been described so far [2]. *L. iners* is a peculiar member, since it has the shortest genome of all lactobacilli [9]. Consequently, this paltry species („iners“, i.e. latin, means idle or iners) lacks some properties of other members such as *Lactobacillus crispatus*, *Lactobacillus jensenii*, and *Lactobacillus gasseri*, which are often associated with *L. iners* for example in the normal vaginal flora [2, 10] playing a decisive role for the homeostasis at this site. Lactobacilli in general produce a lot of bacteriocines sometimes even several ones [11]. These antimicrobial products have usually a narrow spectrum of activity namely against related bacteria but some exert even a broad antimicrobial spectrum including even *Candida*, *Gardnerella*, and *Escherichia coli*. [12]. *L. iners* makes at least one, i.e. inecin L [13].

The prominent character of *L. iners* is, however, that this species attaches rather firmly to fibronectin on the surface of epithelial cells [14]. Indeed, it is the main agent of the local flora in the urinary bladder of women followed by *Lactobacillus kitasatonis* [2, 3] contributing to colonization resistance against uropathogenic bacteria.

This protective local standard flora can be altered by antibiotics given to treat urinary tract infections or to prevent recurrent infections [4].

Since lactobacilli are generally regarded as non-pathogenic except in few cases [5], their antibiotic susceptibility is not well studied [15, 16]. This holds especially true for *L. iners*, which has not yet been tested so far.

Although defined breakpoints *Lactobacillus* spp is not available, the laboratory results should be interpreted rather reluctantly. In general *Lactobacillus* spp. are held to be susceptible to ampicillin [16, 17] as well as to nitrofurantoin [18, 19], but resistant to cotrimoxazole and fosfomycin [5, 15, 18, 20]. In addition, several *Lactobacillus* spp. have been reported to be resistant to nitroxoline [21, 22, 23]. The data about quinolones are rather controversial.

The spectrum of activities of certain antibiotics against *L. iners* – at least under the given test conditions (tab. 1) is divergent. Only fosfomycin and cotrimoxazole are inactive against this bacterium hence sparing possibly the protective local flora in the urinary bladder in women whereas the betalactams, levofloxacin, nitrofurantoin as well as nitroxoline are more or less active in vitro and thus may be harmful to the resident flora of the urinary bladder.

References

1. Magistro G, Stief CG. (2018). The urinary tract microbiome: the answer to all our open questions? *Eur Urol Focus*,5:36-38.
2. Kim J-M, Park Y-J. (2018). Lactobacillus and urine microbiome in association with urinary tract infections and bacterial vaginosis. *Urogenit Tract Infect*,13:7-13.
3. Mora-Vargas CD, Grobeisen-Duque O, Villavicencio-Carrisoza O et al. (2025). Urobiome signatures of recurrent urinary tract infections in adolescent pregnancy: a longitudinal study. *Microorganisms*,13:24-06.
4. Mulder M, Radjabzadeh D, Hassing RJ et al. (2019). The effect of antimicrobial drug use on the composition of the genitourinary microbiota in an elderly population. *BMC Microbiol*,19:9.
5. Guérin F, Sassi M, Gravey F et al. (2025). Lactobacillus delbrueckii subsp. allosunkii and lactis as emerging human uropathogens in elderly patients. *J Clin Microbiol*,63: e0207-224.
6. EFSA (2018). Panel on additives and products or substances used in animal Feed (FEEDAP). Guidance on the characterization of microorganisms used as feed additives or as production organisms. *EFSA J*,6:52-06.
7. NAK - Nationales Antibiotika-Sensitivitätstest-Komitee (2014). Nitroxoline: Rationale for the clinical breakpoints, version 1.0. NAK Dokumente. Grenzwerte. Nitroxolin. www.nak-deutschland.org
8. AWMF (2024). S3-Leitlinie Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei Erwachsenen (HWI). Reg Nr. 043-044 vom 9.4.
9. Zheng J, Wittouck S, Salvetti E et al. (2020). A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. *Int J Syst Evol Microbiol*, 70;2782-2858.
10. Vidhate P, Wakchoure P, Borole S, Khan AA. (2024). Lactobacillus as probiotics: opportunities and challenges for potential benefits in female reproductive health. *Am J Transl Res*,16;720-729.
11. Collins FWJ, O'Connor PM, O'Sullivan O et al. (2017). Bacteriocin gene-trait matching across the complete Lactobacillus pan-genome. *Sci Rep*,7;34-81
12. Kaewsrichan J, Peeyananjarassri K, Kongprasertkit J. (2006). Selection and identification of anaerobic lactobacilli producing inhibitory compounds against vaginal pathogens. *FEMS Immunol Med Microbiol*,48;75-83.
13. Li L, Zhang J, Zhou L et al. (2023). The first lanthipeptide from Lactobacillus iners, inecin L, exerts high antimicrobial activity against human vaginal pathogens. *Appl Environ Microbiol*,89: e0212-322.
14. McMillan A, Macklaim JM, Burton JP et al. (2023). Adhesion of Lactobacillus iners AB-1 to human fibronectin: a key mediator for persistence in the vagina? *Reprod. Sci*,20;791-796.
15. Goldstein EJ, Tyrrell KL, Citron DM. (2015). Lactobacillus species: taxonomic complexity and controversial susceptibilities. *Clin Infect Dis*, (60)20; S98-107.
16. Klare I, Konstabel C, Werner G et al. (2027). Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. *J Antimicrob Chemother*,59;900-12.
17. Stefańska I, Kwiecień E, Józwiak-Piasecka K et al. (2021). Antimicrobial susceptibility of Lactic Acid Bacteria strains of potential use as feed additives - the basic safety and usefulness criterion. *Front Vet Sci*. 2021: 8;687-071.
18. Singhal L, Gupta V, Gupta M et al (2020). Identification and sensitivity of vaginal and probiotic Lactobacillus species to urinary antibiotics. *J Lab Physicians*,12;111-114.
19. Quaresma LS, Santos RCV, Gomes GC et al. (2024). Multidrug resistance profile in Lactobacillus delbrueckii: a food industry species with probiotic properties. *World J Microbiol Biotechnol*,40;235.
20. Anisimova EA, Yarullina DR. (2019). Antibiotic resistance of LACTOBACILLUS strains. *Curr Microbiol*, 76;1407-1416.
21. Nikolaeva IV, Shabanova NA, Bondarenko VM et al. (2010). Species composition and antibiotic resistance of lactobacillus in infants. *Zh Mikrobiol Epidemiol Immunobiol*,6;70-75. Russian.
22. Kudera T, Duskocil I, Salmonova H et al. (2020). In vitro selective growth-inhibitory activities of phytochemicals, synthetic phytochemical analogs, and antibiotics against diarrheagenic/probiotic bacteria and cancer/normal intestinal cells. *Pharmaceuticals (Basel)*,13;233.
23. Osei-Owusu H, Kudera T, Strakova M et al. (2022). In vitro selective combinatory effect of ciprofloxacin with nitroxoline, sanguinarine, and zinc pyrithione against diarrhea-causing and gut beneficial bacteria. *Microbiol Spectr*,10: e0106-322.